Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial
Primary result · Change in HbA1cResult — go to the resultDifference −1.61 to −2.24 %-pointsAuthors' conclusion
CT-868 1.75 to 4.0 mg yielded robust, clinically meaningful decreases in HbA1c, supporting potent glycaemic-lowering effects and improved key lipid parameters in participants with overweight/obesity and T2D, despite modest weight loss. CT-868 was well tolerated, supporting future investigation of higher doses to maximize weight loss.
Study context
- Population
- Adults with T2D, BMI ≥27 kg/m² and HbA1c 7.0–10.0%randomized 1:2:1
- Participants
- 103 adults
- Comparison
- Once-daily CT-868 vs placebo
- CT-868 1.75 mgn = 26
- 3.25 mgn = 18
- 4.0 mgn = 32
- Placebon = 27reference
- Primary endpoint
- Change from baseline in HbA1c
- Follow-up
- W26
Methodological detailsphase 2, double-blind, placebo-controlled
- Phase 2
- Double-blind
- Placebo-controlled
Primary result
Change in HbA1c
Difference
−1.61 to −2.24 %-points
all p < 0.001
As reported in the abstract
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| Body weight change · W264.0 mg vs Placebo | −2.9 % | P < 0.001 |
Fasting glucose, self-monitored blood glucose (SMBG) and lipids
- CT-868 improved fasting glucose, SMBG, and most lipid parameters vs placebo
Safety
- Participants with hypoglycaemia
- 0
- Adverse events (AEs) were mostly mild/moderate
Original publication
Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial. Diabetes Obes Metab. Published 5 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →